CODEN [USA]: IAJPBB ISSN : 2349-7750

INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES

SJIF Impact Factor: 7.187
https://doi.org/10.5281/zenodo.20760076

Available online at: http://www.iajps.com Review Article

THE DEVELOPMENT OF THIRD-GENERATION ANTISEIZURE DRUGS AND SYNAPTIC VESICLE PROTEIN 2A (SV2A) LIGANDS: AN EXTENSIVE ANALYSIS OF CLINICAL EFFECTIVENESS, SAFETY, AND PRACTICAL RESULTS

Kadeejathul Hana KP[1], Fathimath Safa[1], Honey Mariya Babu[1], Rincy K Geevarghese[1], Mrs. Vineetha S[2], Dr. T. Tamilselvan[3]

[1]4TH Semester, M Pharm Students, Department of Pharmacy Practice, Nehru College of Pharmacy, Thiruvilwamala, Thrissur,680588

[2]Associate Professor, Department of Pharmacy Practice, Nehru College of Pharmacy, Thiruvilwamala, Thrissur,680588

[3]HOD & Professor, Department of Pharmacy Practice, Nehru College of Pharmacy, Thiruvilwamala, Thrissur,680588

Abstract:

The advent of tailored, third-generation antiseizure drugs (ASMs) has significantly enlarged the treatment landscape for epilepsy. Targeting the synaptic vesicle protein 2A (SV2A), a crucial regulator of neurotransmitter exocytosis, has been essential to this advancement. Along with other modern ASMs like perampanel, this review examines the preclinical discovery, clinical efficacy, and practical results of well-known SV2A ligands, mainly levetiracetam and its high-affinity counterpart, brivaracetam. By combining data from clinical trials, systematic reviews, we assess how variations in molecular affinity and pharmacokinetic profiles translate into unique therapeutic advantages, specific administration methods, and neuropsychiatric tolerance margins across various patient populations using meta-analyses and real-world observational data.

KEYWORDS: *Brivaracetam (BRV), Levetiracetam (LEV) Antiseizure Medications (ASMs) / Antiepileptic Drugs (AEDs), Behavioral Adverse Events (BAEs), COMPARE study (the prominent real-world comparative study of third-generation ASMs) (Roberti, 2023), SV2A Ligands*

Corresponding author:

Kadeejathul Hana KP,

4th Semester, M. Pharm Students,
Department of Pharmacy Practice,
Nehru College of 2Pharmacy,
Thiruvilwamala, Thrisssur, 680588

QR CODE

Please cite this article in press Kadeejathul Hana KP et al., The Development Of Third-Generation Antiseizure Drugs And Synaptic Vesicle Protein 2a (Sv2a) Ligands: An Extensive Analysis Of Clinical Effectiveness, Safety, And Practical Results, Indo Am. J. P. Sci, 2026; 13(06).

INTRODUCTION:

Over the past few decades, there has been a significant paradigm shift in the discovery and development of antiepileptic medications. Although successful, early anticonvulsant discoveries frequently produced drugs with limited therapeutic windows and substantial metabolic liabilities because to the heavy reliance on phenotypic animal screening models [11]. Clinicians must maximize seizure freedom and patient quality of life in the current era of epilepsy care [26]. In order to overcome the traditional constraints of first- and second-generation agents, this change required a target-based drug development strategy [11].

The discovery of the synaptic vesicle protein 2A (SV2A) as a special, very potent therapeutic location was a significant turning point in this targeted evolution. The central nervous system's synaptic vesicles express SV2A, an integral membrane glycoprotein that is crucial for controlling vesicular exocytosis and calcium-dependent neurotransmitter release.

SV2A LIGAND PHARMACOLOGY AND PRECLINICAL DEVELOPMENT

The first drug found to operate specifically through SV2A binding was the second-generation ASM levetiracetam (LEV) [15,17]. Although LEV showed a good clinical profile, brivaracetam (BRV), its structural equivalent, was logically created to maximize these pharmacodynamic characteristics [4,21].

BRV has a 15–30 times greater binding affinity for the SV2A protein than LEV, according to preclinical research [3]. Additionally, BRV has unique lipid-solubility characteristics that enable a much quicker onset of action and high brain permeability [5]. Compared to its predecessor, BRV exhibits its anticonvulsive and anti-epileptic actions much more quickly due to its quick blood-brain barrier penetration [3,5].

SV2A modification has therapeutic value outside of models of focal epilepsy. The broad-spectrum neurological value of targeting this vesicle protein has been confirmed, for instance, by animal models assessing novel SV2A ligands such as brivaracetam and seletracetam, which have shown notable efficacy in alleviating paroxysmal dystonia in specialized mutant strains [6].

SAFETY AND CLINICAL EFFECTIVENESS LEVETIRACETAM'S PROFILE

For a variety of epileptic phenotypes, levetiracetam continues to be a key monotherapy and adjuvant. Its use is age-neutral, with pediatric cohorts demonstrating consistent linear pharmacokinetics and strong effectiveness [20]. In neurocritical care settings, LEV is often used as acute seizure prevention in addition to maintenance therapy [16].

➢ UNCOMMON ADVERSE EFFECTS AND SPECIAL POPULATIONS

- **PREGNANCY AND BREASTFEEDING:** Choosing the best ASM regimen during pregnancy necessitates weighing teratogenic hazards against maternal seizure control. For women of reproductive potential, LEV monotherapy is one of the recommended first-line alternatives due to its comparatively low risk of significant congenital abnormalities, according to extensive registry data [18].

- **HEMATOLOGICAL SAFETY**: Although LEV has a very good safety margin, doctors need to be on the lookout for unusual toxicities. Levetiracetam-associated pancytopenia is one of the rare but serious hematological consequences that have been reported in the literature and need regular clinical monitoring when suspected [19]

DIRECT AND INDIRECT COMPARISONS: BRIVARACETAM VS. LEVETIRACETAM

Researchers employ systematic reviews and indirect treatment comparisons to assess the relative qualities of LEV and BRV due to the scarcity of direct, large-scale, head-to-head randomized controlled trials (RCTs). Adults with refractory focal seizures were assessed in a seminal meta-analysis and indirect comparison by Zhang et al. [1]. The study found that although both medications are quite successful in reducing seizures, their tolerability profiles are affected by minute dosage changes. In particular, when compared indirectly to equal therapeutic levels of LEV, larger dosages of BRV were linked to a different occurrence of several side effects, like dizziness [1].

THIRD-GENERATION COMPARATIVE EFFICACY ASMS: BRIVARACETAM AND PERAMPANEL

Comparing more recent agents with different modes of action becomes crucial as the arsenal of third-generation ASMs expands. Perampanel (PER) functions as a highly selective, non-competitive antagonist of the postsynaptic AMPA glutamate receptor, whereas BRV targets SV2A.

- **DATA FROM INDIRECT CLINICAL TRIALS**
  Perampanel and brivaracetam appear to have similar success rates in lowering seizure frequency, according to systematic

reviews and indirect treatment comparisons evaluating supplementary therapy for focal-onset seizures (with or without secondary generalization) [7].

- **OBSERVATIONAL DATA FROM THE REAL WORLD**
  Further understanding of how these pharmacodynamic variations manifest in clinical practice can be gained by real-world, retrospective, observational investigations. Individual patient tolerability often influences the decision of brivaracetam and perampanel in routine clinical cohorts [2]. Both medications effectively lower focal-onset episodes, but they have different side-effect profiles; brivaracetam is usually preferred because to its positive behavioral footprint, while perampanel necessitates close observation for behavioral changes or irritability [2,22].

EXTENSIVE REAL-WORLD RESEARCH AND DIGITAL HEALTH INFORMATICS

Comorbidities, long-term retention, and patient compliance must all be taken into consideration when converting clinical trial efficacy into practical efficacy.

- **THE STUDY OF COMPARISON**
  Third-generation ASMs' practical performance was assessed by the multicenter COMPARE study [8]. The findings demonstrated that traditional efficacy tables alone are insufficient for therapy selection [10]. Rather, cross-referencing individual drug pharmacokinetics with patient-specific characteristics such concurrent medication profiles, renal function, and mental history is necessary to optimize long-term retention rates [8,10].

- **TRIAL EMULATION AND MEDICAL INFORMATICS**
  Modern neurology analyzes large-scale electronic health records using medical informatics and simulated clinical trials to supplement traditional observational data [9]. Matching the particular ASM mechanism to the patient's electroclinical condition significantly improves long-term retention and lowers treatment failure rates in clinical practice, according to these informatics-driven comparative investigations [9].

CLINICAL OPTIMIZATION: QUALITY OF LIFE, COMORBIDITIES, AND FORMULATIONS

Physical pharmacological characteristics, patient-specific disease loads, and external psychosocial dynamics all play a significant role in the final effectiveness of an ASM regimen.

- **PHARMACEUTICAL ASPECTS**
  Patient compliance has been directly impacted by industrial innovations. For example, the manufacture of smaller, easier-to-swallow solid oral dosages has been made possible by the use of roll compaction to increase the compactibility of acetam derivatives, therefore reducing the physical barrier to adherence [13].

- **HANDLING NEUROLOGICAL SYNDROMES AND COMORBIDITIES**

Treatment for epilepsy frequently interacts with other serious neurological disorders:

- **BRAIN TUMORS**: Highly specific medications are needed to treat seizures in neuro-oncology patients. The use of non-enzyme-inducing ASMs (such as LEV or BRV) is necessary to avoid harmful drug-drug interactions with concurrent chemotherapy regimens due to the substantial clinical weight of epilepsy in patients with brain tumors [27].

- **ABSENCE SEIZURES**: When treating typical absence epilepsy in young children, clinicians must use proven first-line treatments (such as ethosuximide or valproate), even if SV2A ligands are very helpful for focal and generalized tonic-clonic episodes [12].

- **MIGRAINE AND STROKE PREVENTION:** The wide, varied neuroprotective and preventive roles that antiepileptic structures can play are highlighted by complex neuro-vascular scenarios, such as assessing the clinical value of combination therapy with ASMs for migraine to prevent ischemic stroke in young women [14].

- **ENVIRONMENTAL, PSYCHOSOCIAL, AND COGNITIVE MODULATORS**

Clinicians must consider more than just seizure variables in order to deliver really comprehensive care:

- **COGNITIVE BURDEN:** Neuropsychological deficits are intrinsically linked to conditions such as post-traumatic epilepsy [23]. Successful

rehabilitation depends on choosing an ASM that does not worsen underlying cognitive or memory impairments [23].

- **SPECIALIZED REHABILITATION:** Compared to chronic, long-term epileptic states, specialized inpatient rehabilitation programs have shown greater efficacy in enhancing long-term coping strategies and functional outcomes when implemented during early epilepsy [29].

- **SELF-STIGMA:** Epilepsy continues to have a significant psychosocial impact. According to qualitative research, patients' deep-seated self-stigma seriously impedes their ability to seek medical attention and stick to treatment [24].

- **EXTERNAL ENVIRONMENTAL STRESSORS:** It has been demonstrated that worldwide disruptive events, including the imposition of stringent public health lockdowns, significantly change seizure management and cause sleep problems because of decreased access to medical care and increased anxiety [25]. Similarly, acute SARS-CoV-2 infection's known effects on anxiety, depression, and seizure frequency are examples of direct physiological stresses that demonstrate how systemic immune activation and psychosocial stress interact to destabilize previously well-controlled epileptic patients [30].

CONCLUSION:

The enormous significance of structural optimization in drug design is demonstrated by the creation of target-specific drugs like levetiracetam and brivaracetam. Modern pharmacology has effectively produced fast-acting, very effective treatment alternatives by directly altering molecular affinity and lipid permeability at the SV2A site. However, obtaining the best clinical results necessitates looking beyond conventional trial parameters, as shown by large multicenter registries and digital health informatics. An integrated approach that strikes a balance between precise medication mechanisms and the intricate psychological, cognitive, and practical socioeconomic realities of each patient is necessary for truly effective epilepsy care.

REFERENCES:

1. Zhang L, Li S, Li H, Zou X. Levetiracetam vs. brivaracetam for adults with refractory focal seizures: A meta-analysis and indirect comparison. *Seizure*. 2016 Jul;39:28-33. doi: 10.1016/j.seizure.2016.05.004.
2. Liguori C, Manfredi N, Renna R, Izzi F, Pagliuca M, Pagliuca F, Mercuri NB, Fabio P. Comparison of the effectiveness and tolerability of perampanel and brivaracetam: a real-world, observational, retrospective study.
3. Matagne A, Margineanu DG, Kenda B, Michel P, Klitgaard H. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. *Br J Pharmacol*. 2008 Aug;154(8):1662-71. doi: 10.1038/bjp.2008.198.
4. Russo E, Citraro R, Mula M. The preclinical discovery and development of brivaracetam for the treatment of focal epilepsy. *Expert Opin Drug Discov*. 2017 Nov;12(11):1169-1178. doi: 10.1080/17460441.2017.1366985.
5. Nicolas JM, Hannestad J, Holden D, Kervyn S, Nabulsi N, Tytgat D, Huang Y, Chanteux H, Staelens L, Matagne A, Mathy FX, Mercier J, Stockis A, Carson RE, Klitgaard H. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. *Epilepsia*. 2016 Feb;57(2):201-9. doi: 10.1111/epi.13267.
6. Hamann M, Sander SE, Richter A. Brivaracetam and seletracetam, two new SV2A ligands, improve paroxysmal dystonia in the dt sz mutant hamster. *Eur J Pharmacol*. 2008 Dec 28;601(1-3):99-102. doi: 10.1016/j.ejphar.2008.10.048.
7. Trinka E, Tsong W, Toupin S, Patten A, Wilson K, Isojarvi J, James D. A systematic review and indirect treatment comparison of perampanel versus brivaracetam as adjunctive therapy in patients with focal-onset seizures with or without secondary generalization. *Epilepsy Res*. 2020 Oct;166:106403. doi: 10.1016/j.eplepsyres.2020.106403.
8. Roberti R, Di Gennaro G, Anzellotti F, Arnaldi D, Belcastro V, Beretta S, Boero G, Bonanni P, Canafoglia L, D'Aniello A, Dainese F, De Caro C, Di Gennaro G, Di Giacomo R, DiFrancesco JC, Dono F, Falcicchio G, Ferlazzo E, Foschi N, Franciotta S, Gambardella A, Giordano A, Iannone LF, Labate A, La Neve A, Lattanzi S, Leggio U, Liguori C, Maschio M, Nilo A, Operto FF, Pascarella A, Pauletto G, Renna R, Strigaro G; COMPARE Study Group; Russo E. A real-world comparison among third-generation antiseizure medications: Results from the COMPARE study. *Epilepsia*. 2024 Feb;65(2):456-472. doi: 10.1111/epi.17843.
9. Xie K, Korzun J, Zhou DJ, Chang E, Ghosn NJ, Lavelle S, Oganisian A, Acton EK, Gelfand MA, Roth D, Litt B, Ellis CA. Comparative effectiveness of anti-seizure medications in emulated trials using medical informatics.

Brain. 2025 Dec 4;148(12):4288-4298. doi: 10.1093/brain/awaf238.

10. Comparison Table: Some oral antiseizure medications. *Med Lett Drugs Ther*. 2024 Aug 5;66(1708):e133-e140. doi: 10.58347/tml.2024.1708b.
11. Klitgaard H. Antiepileptic drug discovery: lessons from the past and future challenges. *Acta Neurol Scand Suppl*. 2005;181:68-72. doi: 10.1111/j.1600-0404.2005.00513.x.
12. Vrielynck P. Current and emerging treatments for absence seizures in young patients. *Neuropsychiatr Dis Treat*. 2013;9:963-75. doi: 10.2147/NDT.S30991.
13. Kuntz T, Martin AS, Kleinebudde P. Increased compactibility of acetames after roll compaction. *Eur J Pharm Biopharm*. 2011 Jan;77(1):164-9. doi: 10.1016/j.ejpb.2010.09.013.
14. Konstantinos F, Tsolaki V, Georgakopoulou VE, Aravantinou A, Fotakopoulos G. Value of Combination Therapy With Antiepileptic Drugs (AEDs) for Migraine to Prevent Ischemic Stroke in Young Women.
15. Howard P, Remi J, Remi C, Charlesworth S, Whalley H, Bhatia R, Hitchens M, Mihalyo M, Wilcock A. Levetiracetam. *J Pain Symptom Manage*. 2018 Oct;56(4):645-649. doi: 10.1016/j.jpainsymman.2018.07.012.
16. Fang T, Valdes E, Frontera JA. Levetiracetam for Seizure Prophylaxis in Neurocritical Care: A Systematic Review and Meta-analysis. *Neurocrit Care*. 2022 Feb;36(1):248-258. doi: 10.1007/s12028-021-01296-z.
17. Nash EM, Sangha KS. Levetiracetam. *Am J Health Syst Pharm*. 2001 Jul 1;58(13):1195-9. doi: 10.1093/ajhp/58.13.1195.
18. Kaplan YC, Demir O. Use of Phenytoin, Phenobarbital Carbamazepine, Levetiracetam Lamotrigine and Valproate in Pregnancy and Breastfeeding: Risk of Major Malformations, Dose-dependency, Monotherapy vs Polytherapy, Pharmacokinetics and Clinical Implications. *Curr Neuropharmacol*. 2021;19(11):1805-1824. doi: 10.2174/1570159X19666210211150856.
19. Unkun R, Kochan Kizilkilic E, Delil S, Kemerdere R, Ozkara C. Levetiracetam-associated pancytopenia. *Acta Neurol Belg*. 2023 Aug;123(4):1625-1626. doi: 10.1007/s13760-022-02138-1.
20. Vigevano F. Levetiracetam in pediatrics. *J Child Neurol*. 2005 Feb;20(2):87-93. doi: 10.1177/08830738050200020101.
21. Klein P, Bourikas D. Narrative Review of Brivaracetam: Preclinical Profile and Clinical Benefits in the Treatment of Patients with Epilepsy. *Adv Ther*. 2024 Jul;41(7):2682-2699. doi: 10.1007/s12325-024-02876-z.
22. Hwang H, Kim WJ. Brivaracetam: Pharmacology, Clinical Efficacy, and Safety in Epilepsy.
23. Kuo JR, Su BY. Neuropsychological Impairments in Patients With Post-traumatic Epilepsy: A Scoping Review. *World Neurosurg*. 2023 Aug;176:85-97. doi: 10.1016/j.wneu.2023.04.101.
24. Kuramochi I, Horikawa N, Shimotsu S, Hiwatashi T, Watanabe M, Okazaki M, Yoshimasu H. The self-stigma of patients with epilepsy in Japan: A qualitative approach. *Epilepsy Behav*. 2020 Aug;109:106994. doi: 10.1016/j.yebeh.2020.106994.
25. Conde Blanco E, Manzanares I, Centeno M, Khawaja M, Betrán O, Donaire A, Carreño M. Epilepsy and lockdown: A survey of patients normally attending a Spanish centre. *Acta Neurol Scand*. 2021 Feb;143(2):206-209. doi: 10.1111/ane.13354.
26. Bertran F. [Epilepsy today]. *Rev Infirm*. 2018 Aug-Sep;67(243):14-16. doi: 10.1016/j.revinf.2018.07.003.
27. Maschio M, Sperati F, Dinapoli L, Vidiri A, Fabi A, Pace A, Pompili A, Carapella CM, Cantelmi T. Weight of epilepsy in brain tumor patients. *J Neurooncol*. 2014 Jun;118(2):385-393. doi: 10.1007/s11060-014-1449-7.
28. Glauser TA. Following catastrophic epilepsy patients from childhood to adulthood. *Epilepsia*. 2004;45 Suppl 5:23-6. doi: 10.1111/j.0013-9580.2004.05005.x.
29. Hagemann A, Lahr D, May TW, Speicher P, Hausfeld H, Coban I, Müffelmann B, Bien CG, Specht U. Efficacy of a specialized inpatient rehabilitation program in patients with early versus chronic epilepsy. *Epilepsy Behav*. 2023 May;142:108999. doi: 10.1016/j.yebeh.2022.108999.
30. Zhou S, Zhang D, Chang J, Xia Z, Li J, Ni M, Li H. Effect of SARS-CoV-2 infection on seizure, anxiety, and depression in 107 patients with epilepsy. *Epilepsy Behav*. 2023 Aug;145:109290. doi: 10.1016/j.yebeh.2023.109290.